Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas

Silvana Novelli, Anna Monter, M. Pilar García-Muret, Rodrigo Martino, Javier Briones, Jorge Sierra

Producció científica: Contribució a revistaArticle de revisióRecercaAvaluat per experts

1 Citació (Scopus)

Resum

© 2019, Japanese Society of Hematology. Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.
Idioma originalAnglès
Pàgines (de-a)406-410
RevistaInternational Journal of Hematology
Volum110
Número4
DOIs
Estat de la publicacióPublicada - 1 d’oct. 2019

Fingerprint

Navegar pels temes de recerca de 'Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas'. Junts formen un fingerprint únic.

Com citar-ho